BioNTech, Duality Biologics Enter Licensing Agreement for Cancer Treatments
03 Abril 2023 - 08:49AM
Dow Jones News
By Chris Wack
Biopharmaceutical companies BioNTech SE and Duality Biologics
(Suzhou) Co. Ltd. have entered into exclusive license and
collaboration agreements to develop, manufacture and commercialize
two antibody-drug conjugate assets (ADCs) globally, excluding
mainland China, Hong Kong and Macau.
Germany-based BioNTech said that with the collaboration, ADCs
would become an additional drug class in its oncology portfolio.
BioNTech would gain access to Shanghai-based DualityBio's lead
candidate, DB-1303, a topoisomerase-1 inhibitor-based ADC directed
against Human Epidermal Growth Factor Receptor 2, as well as a
second topoisomerase-1 inhibitor-based ADC candidate, DB-1311.
ADCs are a class of potent cancer therapies combining the
selectivity of antibodies with the potent cell-killing properties
of chemotherapy or other anti-cancer agents.
The DB-1303 program has received a Fast Track designation from
the U.S. Food and Drug Administration and is currently in a Phase 2
clinical trial for treatment of HER2-expressing advanced solid
tumors.
For both assets, DualityBio would receive single-digit to
double-digit tiered royalties on net sales, upfront licensing
payments totaling $170 million, and additional development,
regulatory and commercial milestone payments potentially totaling
over $1.5 billion.
BioNTech would hold commercial rights globally, while DualityBio
would retain commercial rights for mainland China, Hong Kong and
Macau. For DB-1311, DualityBio also has the right to exercise a
co-promotion option and a co-development cost and profit-loss
sharing option.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 03, 2023 07:34 ET (11:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024